Abstract：Objective To compare the clinical effect of intravitreal injection of Conbercept and Ranibizumab in the treatment of wet age-related macular degeneration (AMD).Methods A total of 100 cases of wet AMD patients (100 eyes) treated in the Fourth People′s Hospital of Shenyang City from November 2016 to November 2017 were selected.The patients were diagnosed by examining the early treatment diabetic retinopathy study (ETDRS) visual acuity chart,optical coherence tomography (OCT), fundus fluorescein angiography (FFA), etc.The patients were divided into the Conbercept and the Ranibizumab groups by random number table methods, with 50 cases in each group (50 eyes).In the Conbercept treatment group, intravitreal injection of 0.05 ml Conbercept (10 g/L with 0.5 mg Conbercept).In the Ranibizumab treatment group, intravitreal injection of 0.05 ml Ranibizumab (10 g/L with 0.5 mg Ranibizumab).After 12-month follow-up, the ETDRS visual acuity, foveal retinal thickness and choroidal neovascularization (CNV) leakage before and after treatment were compared in the two groups.Results There was no significant difference in the ETDRS visual acuity or foveal retinal thickness between the two groups before treatment (P>0.05).After treatment, the visual acuity of ETDRS was higher than that before treatment, and the thickness of foveal retina was less than that before treatment, the differences were statistically significant (P<0.05).There was no significant difference in the visual acuity of ETDRS or the thickness of foveal retina in the two groups after treatment (P>0.05).On comparison of the CNV leakage, there was no significant difference (P>0.05).The number of injections in the conbercept group was less than that in the ranibizumab group (P<0.05).There were no ocular and systemic adverse reactions related to injection or drug during the follow-up period.Conclusion Intravitreal injection of Conbercept and Ranibizumab in the treatment of wet AMD has a good effect, can markedly improve the patients′ vision, reduce macular edema, and effectively inhibit the leakage of new blood vessels, but during the follow-up, the number of drug injections in the Conbercept treatment group was greatly less than that in the Ranibizumab treatment group.From an economic point of view, the medical expenses paid by the patients can be saved to some extent in the former.
京公网安备 11010502046607号